On October 17, 2019, the final symposium of the Major New Drug Creation Project "Phase I/II Clinical Research of CHA for Injection, a First-Created Class 1 New Drug" was held at the Institute of Materia Medica, Chinese Academy of Medical Sciences. The symposium was presided over by Zhang Jie, General Manager of Sichuan Jiuzhang Biotechnology Co., Ltd. Jiang Jiandong, Director of the Institute of Materia Medica, delivered a welcome speech, and Hu Jinfeng, Director of the Scientific Research Department, introduced the participants.

The "4th China Pharmaceutical Innovation and Investment Conference" grandly opened on September 21, 2019, at the Jinji Lake International Conference Center in Suzhou, Jiangsu Province, China. Guests from the four well - known global stock exchanges (Hong Kong, NASDAQ, London, and Shanghai Stock Exchanges) and top immunotherapy scientists gathered on the scene. They heatedly discussed the financing policies of globally leading financing platforms for pharmaceutical innovation enterprises, helped domestic biomedical enterprises find suitable cross - border financing channels, and promoted the improvement of the innovation and transformation capabilities of China's pharmaceutical industry.

The clinical trial titled "A Randomized, Controlled, Open-Label, Multi-center, Phase II/III Clinical Study to Evaluate the Safety and Efficacy of CHA for Injection in the Treatment of Recurrent Grade IV Glioblastoma (GBM)" was officially launched at Chongqing University Cancer Hospital on April 25, 2019, and at Cancer Hospital of Harbin Medical University on May 7, 2019. It publicly recruited recurrent glioblastoma patients who met the inclusion criteria from the society.

After being reviewed and approved by the Ethics Committee of Beijing Tiantan Hospital Affiliated to Capital Medical University (Ethics Review No. YW2018 - 018 - 01/02/03), the clinical trial titled "A Randomized, Controlled, Open - Label, Multi - center, Phase II/III Clinical Study to Evaluate the Safety and Efficacy of CHA for Injection in the Treatment of Recurrent Grade IV Glioblastoma (GBM)", presided over by Professor Li Wenbin, Director of the Comprehensive Treatment Ward for Neuro - Oncology in the Department of Neurosurgery of Beijing Tiantan Hospital, has been officially launched. After the Spring Festival in 2019, recruitment of recurrent glioblastoma patients who meet the inclusion criteria will officially start from the general public.

The "3rd China Pharmaceutical Innovation and Investment Conference" was held at the Conference Center of Suzhou Bio-industry Park on September 18, 2018. At the conference, Jiuzhang Biotech delivered a special report titled "Review of Phase I Clinical Data of CHA for Injection, a Natural Small-Molecule Innovative Drug for Glioma Treatment, and Prospects for Phase II Clinical Trials".

On May 19, 2018, the "Discussion Meeting on the Clinical Trial Protocol for CHA for Injection in the Treatment of GBM Phase II/III" organized by our company (the sponsor) came to a successful conclusion.